Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Reviews on Recent Clinical Trials
  4. Volume 20, Issue 2
  5. Article
Volume 20, Issue 2
  • ISSN: 1574-8871
  • E-ISSN: 1876-1038

Abstract

Background

infection is the main cause of most PUD; therefore, the eradication of is extremely important in the treatment of PUD. There are several recommended treatment regimens suggested to eradicate this organism.

Aim

This study compared the efficacy of three anti- regimens in patients with dyspepsia or peptic ulcer disease (PUD).

Objective

The objective of this study was to assess the efficacy of three anti- treatments in patients based on C14 urease breath test (C-UBT) results, drug compliance, and adverse effects.

Methods

This randomized, open-label clinical trial included 136 -infected patients without prior treatment. Patients were randomly divided into three groups. The OAC group received 20 mg Omeprazole capsules twice a day, two 500 mg Amoxicillin capsules twice a day, and 500 mg Clarithromycin capsules twice a day for 14 days. The OAL group received 20 mg Omeprazole capsules twice a day, two 500 mg Amoxicillin capsules twice a day, and Levofloxacin 500 mg capsules twice a day for 14 days. The OAMB group received 20 mg Omeprazole capsules twice a day, two 500 mg Amoxicillin capsules twice a day, Metronidazole 500 mg three times a day, and Bismuth 240 mg twice a day for 14 days. Evaluation for compliance and drug-related adverse effects were assessed at the end of two weeks. eradication was evaluated eight weeks after treatment using the C-UBT.

Results

A total of 136 patients participated in this study, and their groups were matched based on age and sex. The results of the C-UBT test showed that the eradication rate of was 82.2%, 91.3%, and 97.3% for the three-drug OAC, OAMB, and OAL treatment regimens, respectively. Moreover, all the regimens showed high compliance among the patients. Only OAC and OAL showed a significant difference in the eradication rate, and no superiority was found between OAMB and OAL or OAC therapies.

Conclusion

The regime of OAL achieved a satisfactory rate of infection eradication with good tolerance in patients with PUD, without any acute side effects.

Clinical Trial Registration Number

IRCT201605189014N100.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/rrct/10.2174/0115748871306001241017050020
2024-10-30
2025-04-23

  • From This Site

    /content/journals/rrct/10.2174/0115748871306001241017050020
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LanasA. ChanF.K.L. Peptic ulcer disease.Lancet20173901009461362410.1016/S0140‑6736(16)32404‑728242110
     [Google Scholar]
  2. VakilN. Dyspepsia, peptic ulcer, and H. pylori : A remembrance of things past.Am. J. Gastroenterol.2010105357257410.1038/ajg.2009.70920203639
     [Google Scholar]
  3. MarieM.A.M. AltahirI.E. Relationship between the extent of DNA damage and gastritis in normal and Helicobacter pylori-infected patients.Gut Liver20115331532010.5009/gnl.2011.5.3.31521927660
     [Google Scholar]
  4. XieX. RenK. ZhouZ. DangC. ZhangH. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: A population-based study.BMC Gastroenterol.20222215810.1186/s12876‑022‑02130‑235144540
     [Google Scholar]
  5. KavittR.T. LipowskaA.M. Anyane-YeboaA. GralnekI.M. Diagnosis and treatment of peptic ulcer disease.Am. J. Med.2019132444745610.1016/j.amjmed.2018.12.00930611829
     [Google Scholar]
  6. SverdénE. AgréusL. DunnJ.M. LagergrenJ. Peptic ulcer disease.BMJ2019367l549510.1136/bmj.l549531578179
     [Google Scholar]
  7. MustafaM. MenonJ. MuiandyR. FredieR. SeinM. FarizA. Risk factors, diagnosis, and management of peptic ulcer disease.IOSR J. Dent. Med. Sci.20151474046
     [Google Scholar]
  8. NegashM. Wondifraw BaynesH. GeremewD. Helicobacter pylori infection and its risk factors: A prospective cross-sectional study in resource-limited settings of Northwest Ethiopia.Can J Infect Dis Med Microbiol20182018946371010.1155/2018/9463710
     [Google Scholar]
  9. FischbachW. MalfertheinerP. Helicobacter pylori infection.Dtsch. Arztebl. Int.20181152542943629999489
     [Google Scholar]
  10. FitzGeraldR. SmithS.M. An overview of Helicobacter pylori infection.Methods Mol. Biol.2021228311410.1007/978‑1‑0716‑1302‑3_133765303
     [Google Scholar]
  11. CroweS.E. Helicobacter pylori infection.N. Engl. J. Med.2019380121158116510.1056/NEJMcp171094530893536
     [Google Scholar]
  12. PohlD. KellerP.M. BordierV. WagnerK. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing.World J. Gastroenterol.201925324629466010.3748/wjg.v25.i32.462931528091
     [Google Scholar]
  13. LeeS.W. KimH.J. KimJ.G. Treatment of Helicobacter pylori infection in Korea: A systematic review and meta-analysis.J. Korean Med. Sci.20153081001100910.3346/jkms.2015.30.8.100126240475
     [Google Scholar]
  14. O’ConnorA. FurutaT. GisbertJ.P. O’MorainC. Review – Treatment of Helicobacter pylori infection 2020.Helicobacter202025S1e1274310.1111/hel.1274332918350
     [Google Scholar]
  15. SharifZ. MubashirM. NaqviM. AtiqueH. MahmoodS. UllahM. Randomized clinical trial on the efficacy of triple therapy versus sequential therapy in Helicobacter pylori eradication.Cureus2022145e2489710.7759/cureus.2489735706754
     [Google Scholar]
  16. SalmanroghaniH. MirvakiliM. BaghbanianM. SalmanroghaniR. SanatiG. YazdianP. Efficacy and tolerability of two quadruple regimens: Bismuth, omeprazole, metronidazole with amoxicillin or tetracycline as first-line treatment for eradication of Helicobacter pylori in patients with duodenal ulcer: A randomized clinical trial.PLoS One2018136e019709610.1371/journal.pone.019709629889843
     [Google Scholar]
  17. CalvetX. Dealing with uncertainty in the treatment of Helicobacter pylori.Ther. Adv. Chronic Dis.2018949310210.1177/204062231875824029623181
     [Google Scholar]
  18. Adachi T. Matsui S. Watanabe T. et al. Comparative study of clarithromycin- versus metronidazole-based triple therapy as first line eradication for Helicobacter pylori. Oncology 20279315910.1159/00048122429258111
    [Google Scholar]
  19. LopoI. LibânioD. PitaI. Dinis-RibeiroM. Pimentel-NunesP. Helicobacter pylori antibiotic resistance in Portugal: Systematic review and meta-analysis.Helicobacter2018234e1249310.1111/hel.1249329911329
     [Google Scholar]
  20. PeretzA. ParitskyM. NasserO. BrodskyD. GlyatmanT. SegalS. OnA. Resistance of Helicobacter pylori to tetracycline, amoxicillin, clarithromycin and metronidazole in Israeli children and adults.J. Antibiot. (Tokyo)201467855555710.1038/ja.2014.3824781955
     [Google Scholar]
  21. HongT.C. El-OmarE.M. KuoY.T. WuJ.Y. ChenM.J. ChenC.C. FangY.J. LeowA.H.R. LuH. LinJ.T. TuY.K. YamaokaY. WuM.S. LiouJ.M. HongT-C. El-OmarE.M. KuoY-T. WuJ-Y. ChenM-J. ChenC-C. FangY-J. LeowA.H.R. LuH. LinJ-T. TuY-K. YamaokaY. WuM-S. LiouJ-M. ChenY-C. ChangY-Y. Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: An updated systematic review and meta-analysis.Lancet Gastroenterol. Hepatol.202491566710.1016/S2468‑1253(23)00281‑937972625
     [Google Scholar]
  22. ValleJ.D. Peptic ulcer disease and related disorders.Harrison’s Principles of Internal Medicine LoscalzoJ. FauciA. KasperD. HauserS. LongoD. JamesonJ.L. New York, NYMcGraw-Hill Education2022
     [Google Scholar]
  23. LiB. LanX. WangL. ZhaoJ. DingJ. DingH. LeiJ. WeiY. ZhangW. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori : A meta-analysis.Microb. Pathog.202014210407510.1016/j.micpath.2020.10407532074497
     [Google Scholar]
  24. PuigI. BaylinaM. Sánchez-DelgadoJ. López-GongoraS. SuarezD. García-IglesiasP. MuñozN. GisbertJ.P. DacollC. CohenH. CalvetX. Systematic review and meta-analysis: Triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment.J. Antimicrob. Chemother.201671102740275310.1093/jac/dkw22027342548
     [Google Scholar]
  25. AdachiT. MatsuiS. WatanabeT. OkamotoK. OkamotoA. KonoM. YamadaM. NagaiT. KomedaY. MinagaK. KamataK. YamaoK. TakenakaM. AsakumaY. SakuraiT. NishidaN. KashidaH. KudoM. Comparative study of clarithromycin- versus metronidazole-based triple therapy as first-line eradication for Helicobacter pylori.Oncology201793151910.1159/00048122429258111
     [Google Scholar]
  26. KeikhaM. AskariP. GhazviniK. KarbalaeiM. Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: A systematic review and meta-analysis.J. Glob. Antimicrob. Resist.20222942042910.1016/j.jgar.2021.10.01934788690
     [Google Scholar]
  27. AzabE.T. ThabitA.K. McKeeS. Al-QiraiqiriA. Levofloxacin versus clarithromycin for Helicobacter pylori eradication: Are 14 day regimens better than 10 day regimens?Gut Pathog.20221412410.1186/s13099‑022‑00502‑335668511
     [Google Scholar]
  28. Cuadrado-LavínA. Salcines-CaviedesJ.R. CarrascosaM.F. Dierssen-SotosT. CoboM. CamposM.R. AyestaránB. Fernández-PousaA. González-ColominasE. Aresti-ZárateS. HernándezM. PascualE.L. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: A single-blind randomized clinical trial.J. Antimicrob. Chemother.20126792254225910.1093/jac/dks20922687889
     [Google Scholar]
  29. BangC.S. LimH. JeongH.M. ShinW.G. ChoiJ.H. SohJ.S. KangH.S. YangY.J. HongJ.T. ShinS.P. SukK.T. LeeJ.J. BaikG.H. KimD.J. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection.Gut Microbes20201151314132310.1080/19490976.2020.175411832362221
     [Google Scholar]
  30. TianX. SuoB. ZhangH. LuH. LiC. ZhangY. RenX. YaoX. ZhouL. SongZ. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.Helicobacter2023281e1293510.1111/hel.1293536374159
     [Google Scholar]
  31. Hopewell S. Hirst S. Collins GS. Mallett S. YuL-M. Altman DG. Reporting of participant flow diagrams in published reports of randomized trials.Trials 201112110
     [Google Scholar]
/content/journals/rrct/10.2174/0115748871306001241017050020
Loading
The Efficacy of Two Triple Therapy Regimens and One Quadruple Regimen [Omeprazole, Amoxicillin, Metronidazole with Bismuth] in Eradicating Helicobacter pylori in Patients with Peptic Ulcer: A Randomized Clinical Trial
Rev. Recent Clin. Trials 20, 160 (2025); https://doi.org/10.2174/0115748871306001241017050020
/content/journals/rrct/10.2174/0115748871306001241017050020
/content/journals/rrct/10.2174/0115748871306001241017050020
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): antimicrobial; eradication therapy; Helicobacter pylori; Peptic ulcer disease; randomized trial; triple therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test